# Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)

> **NCT01747083** · PHASE1 · COMPLETED · sponsor: **LG Life Sciences** · enrollment: 24 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))

## Key facts

- **NCT ID:** NCT01747083
- **Lead sponsor:** LG Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2013-03
- **Final completion:** 2013-04
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01747083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01747083, "Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01747083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*